Treatment for High-Risk Neuroblastoma
The intensity of neuroblastoma treatment will vary depending on the risk group assigned to your child’s disease. If your child has high-risk neuroblastoma, you can find information about their treatment in this section. To learn about risk groups overall, you can find information on the Understanding the Treatment Options page.
The treatment goal for children with high-risk neuroblastoma is to prevent neuroblastoma from coming back (relapse). Survival rates are poor for high-risk neuroblastoma patients after relapse, and that’s why the treatment for high-risk neuroblastoma uses multiple intensive therapies.
Multiple therapies are used to treat high-risk neuroblastoma
High-risk neuroblastoma can be aggressive and difficult to treat. It will require intensive treatment with multiple types of therapy. This approach has significantly improved survival rates, and research is now focused on new treatments to further improve survival rates.
See NCCN guidelines for more detailed guidelines.
The standard treatment regimen for high-risk neuroblastoma at most hospitals is broken into 3 phases and lasts about 18 months.
Select a topic to learn more about each phase of treatment.
* Please note that some parts of treatment may take place at different hospitals due to need of resources or staffing.Consolidation
The next phase of your child’s treatment for high-risk neuroblastoma is known as consolidation. The consolidation phase will usually include:
- High-dose chemotherapy (myeloablative) with autologous stem cell transplant
- Radiation therapy
Just as in the induction phase, the exact treatment your child receives will depend on the treatment plan set forth by their oncologist. Most hospitals now use tandem stem-cell transplant (2 transplants back to back) and radiation therapy for consolidation treatment. In a recent clinical trial, children who had 2 transplants experienced comparable side effects and had lower rates of relapse compared to children who received a single transplant.
The type of transplant that will be used in neuroblastoma is called an autologous stem cell transplant. This process involves giving the child high-dose chemotherapy to kill the cancer cells. This chemotherapy is so strong that it also kills the healthy stem cells in the child’s bone marrow. For this reason, children are always given a stem cell transplant after high-dose chemotherapy to rescue their bone marrow. This is why a stem cell transplant is sometimes called a bone marrow transplant.
Ask your child’s oncologist about the therapies they plan to use as part of your child’s treatment.
Stem cell transplant
What is a stem cell transplant?
You may hear your child’s healthcare team mention stem cell transplant as part of treatment. This process includes both high-dose chemotherapy and autologous stem cell transplant.
How is a stem cell transplant done?
After your child completes high-dose chemotherapy, the child’s frozen stem cells are thawed and given as an infusion through their central line. The stem cells travel through the child’s bloodstream to the bone marrow.
How long will my child be in the hospital for the consolidation phase?
Usually, children will be admitted to the hospital the day before or the day of high-dose chemotherapy and stay until the new stem cells have started making new blood cells. This process usually takes a few weeks, so plan on your child being in the hospital for at least 3 to 4 weeks.
Radiation therapy
Radiation therapy kills the neuroblastoma cells by using high-energy rays or particles aimed at a specific area. Radiation may be given to the primary tumor site. Even if the tumor was completely removed, it is possible that a very small (microscopic) amount of tumor was left behind.
Your child’s oncologist may also recommend radiation to sites of metastatic disease (places where disease has spread) that have not completely responded to other therapies.
Common side effects of radiation
Short-term side effects may include:
Postconsolidation (antibody therapy)
The last phase of standard therapy for high-risk neuroblastoma is called postconsolidation or antibody therapy. This phase of treatment will be given after your child’s stem cell transplant and uses monoclonal antibodies, cytokines, and retinoic acid.
Antibody therapy
How does antibody therapy work?
Antibody therapy helps to find remaining neuroblastoma cells that are hiding inside of your child’s body so the immune system can destroy them.
How is antibody therapy given?
Antibody therapy is administered through a vein (intravenously) using the central line.
Most hospitals prefer to give antibody therapy in the hospital. This allows for your child to be monitored by their healthcare team and to receive immediate help if they experience any side effects.
Antibody therapy may be given with other medicines:
- Cytokines to boost the immune system
- A differentiating agent (cis-retinoic acid) to help neuroblastoma cells mature
What are the side effects of antibody therapy?
When your child receives antibody therapy, they will also receive premedications (premeds) to help reduce the severity of some side effects. However, some side effects may still occur during antibody therapy. Common side effects may include:
Antibody therapy has greatly improved survival for children with high-risk neuroblastoma and is an essential component to high-risk neuroblastoma treatment.
After your child completes the last phase of high-risk neuroblastoma treatment, it will mark another milestone in your treatment journey. This allows you and your family to start thinking about the future. Once treatment is complete, your child will enter follow-up care, where they will be monitored over the next weeks, months, and years.